NLA101 in Adults Receiving High Dose Chemotherapy for AML

Summary

Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.

Timeline

Start

2018-01-24

Primary completion

2019-03-18

Completion

2019-03-18

Drugs

Indications